AU Patent

AU2024292423A1 — Pharmaceutical compositions comprising a menin inhibitor

Assigned to Kura Oncology Inc · Expires 2026-01-22 · 0y expired

What this patent protects

Provided herein are crystalline forms of (S) -4-methyl-5- ( (4- ( (2- (methylamino) -6- (2, 2, 2-trifluoroethyl) thieno [2, 3-d] pyrimidin-4-yl) amino) piperidin-1-yl) methyl) -1- (2- (4-(methylsulfonyl) piperazin-1-yl) propyl) -1H-indole-2-carbonitrile or solvate thereof, method…

USPTO Abstract

Provided herein are crystalline forms of (S) -4-methyl-5- ( (4- ( (2- (methylamino) -6- (2, 2, 2-trifluoroethyl) thieno [2, 3-d] pyrimidin-4-yl) amino) piperidin-1-yl) methyl) -1- (2- (4-(methylsulfonyl) piperazin-1-yl) propyl) -1H-indole-2-carbonitrile or solvate thereof, methods of making such forms, and pharmaceutical composition comprising such forms.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024292423A1
Jurisdiction
AU
Classification
—
Expires
2026-01-22
Drug substance claim
No
Drug product claim
No
Assignee
Kura Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.